Navigation Links
Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
Date:12/6/2007

PITTSBURGH, Dec. 6 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced that it has received net proceeds after fees and commissions of $26.2 million following completion of the sale of 1.94 million shares of common stock pursuant to the underwriters' partial exercise of the overallotment option granted in connection with its recently completed common stock offering. The overallotment option was exercised at the offering price of $14 per share.

After giving effect to this transaction, MYL has approximately 304 million shares of common stock outstanding.

The joint book-running managers for the common stock offering were Merrill Lynch & Co. and Goldman, Sachs & Co. Merrill Lynch & Co. is acting as sole global coordinator for all financings for Mylan. Co-managers for the common stock offering are Citi, JPMorgan and Cowen and Company.

Copies of the prospectuses related to the offerings may obtained from Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department or from Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, Fax: 212-902-9316 or email at prospectus-ny@ny.email.gs.com.

This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

This press release contains statements that constitute "forward-looking statements", including with regard to the Company's securities offerings. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the prevailing conditions in the public capital markets; significant fluctuations in interest rates or inflation; economic recession; economic, political and market factors affecting trading volumes, securities prices or demand for the Company's stock; and the other risks detailed in the Company's prospectus supplements and in periodic filings filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
3. Mylan Announces Final FDA Approval for Carvedilol Tablets
4. Mylan Announces Tentative FDA Approval for Topiramate Capsules
5. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
6. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... , ... January 15, 2017 , ... The Gravity Vault ... in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, ... Vaults sixth location, including three in New Jersey and two in New York. With ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to ... magnesium-rich Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and ... many health and wellness benefits linked to a Mediterranean diet are only some ...
(Date:1/13/2017)... California (PRWEB) , ... January 13, 2017 , ... ... carbohydrates that raise blood sugar levels. Counting carbohydrates is as easy as checking ... the only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can ...
(Date:1/13/2017)... ... ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth barcode scanners and mobile ... collector at the National Retail Federation’s Big Show (NRF17) held January 15-17 in New ... need for more compact and rugged devices for collecting barcode data paired with a ...
(Date:1/13/2017)... , ... January 13, 2017 , ... An inventor from ... black or brown belt in order to diversify my outfits, so he decided to ... wear. , THE T.O.O.B. enhances the appearance of a belt to allow for quick, ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... 2017 Constant research ongoing in the ... contribute to the demand for western blotting technique. The global  ... US$ 551.0 Mn by 2016 end. Developing economies in ... markets for western blotting, whereas North America ... ...
(Date:1/13/2017)... 13, 2017  Alfalfa, cattle, leafy greens and rosy cheeked ... film , which emphasizes the food industry,s shift from response ... COPAN,s Swab Rinse Kit (SRK™) ... sampling process in the wake of the new FDA ... COPAN is expanding the U.S. production of the ...
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
Breaking Medicine Technology: